Grayling

Innovative trial approaches in immune-mediated inflammatory diseases: Current use and future potential

*BMC Rheumatology* 2021; 5:21

Accounting for variation in the required sample size in the design of group-sequential trials

*Contemporary Clinical Trials* 2021; 107:106459

A review of Bayesian perspectives on sample size derivation for confirmatory trials

*The American Statistician* 2021; DOI:10.1080/00031305.2021.1901782

Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods

*Pharmaceutical Statistics* 2021; doi:10.1002/pst.2119

PSU4 Value of information for adaptive trials: Proof of concept study in multi-arm multi-stage trials of interventions for the prevention of surgical site infections

*Value in Health* 2020; 23(S2):S738

Ambulance documentation of stroke symptoms during the UK COVID-19 'Stay at Home' message

*Emergency Medicine Journal* 2020; 38:83-84

Impact of the COVID-19 lockdown on hangings attended by emergency medical services

*Resuscitation* 2020; 157:89-90

A stochastically curtailed two-arm randomised phase II trial design for binary outcomes

*Pharmaceutical Statistics* 2020; 20(2):212-228

Increasing power in the analysis of responder endpoints in rheumatology: a software tutorial

*medRxiv* 2020

A review of available software for adaptive clinical trial design

*Clinical Trials* 2020;17(3):323-331